Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.

Meissner, H C; Welliver, R C; Chartrand, S A; Law, B J; Weisman, L E; Dorkin, H L; Rodriguez, W J

Meissner, H C; Welliver, R C; Chartrand, S A; Law, B J; Weisman, L E; Dorkin, H L; Rodriguez, W J.

Affiliation

Meissner HC; Department of Pediatrics, New England Medical Center, Tufts University School of Medicine, Boston, Mass 02111, USA. cmeissner@es.nemc.org

Pediatr Infect Dis J ; 18(3): 223-31, 1999 Mar.

Article in En | MEDLINE | ID: mdl-10093942

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Respiratory Syncytial Viruses / Respiratory Syncytial Virus Infections / Antibodies, Monoclonal Type of study: Etiology_studies / Risk_factors_studies Limits: Humans / Infant / Newborn Language: En Journal: Pediatr Infect Dis J Journal subject: DOENCAS TRANSMISSIVEIS / PEDIATRIA Year: 1999 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Search on Google

Add to My VHL

XML

PubMed Links